NCT00450814View on ClinicalTrials.gov

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

July 10, 2018

Study Completion Date

November 20, 2019

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Cyclophosphamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER